Overview

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

Status:
Completed
Trial end date:
2020-01-30
Target enrollment:
Participant gender:
Summary
Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study
Phase:
Phase 1
Details
Lead Sponsor:
Collaborative Medicinal Development Pty Limited
Treatments:
Copper